

Development of a Lung-Selective RNA Therapeutic Candidate for lung fibrosis

Samyang Biopharm.
SAMYANG
 BIOPHARM

RESPIRATORY	Candidate
Product Type	Gene & Nucleic acids
Indication	Idiopathic Pulmonary Fibrosis
Target	****
MoA(Mechanism of Action)	As a first-in-class lung-selective mRNA therapeutic for IPF, our candidate fundamentally restores **** to inhibit the central, TGF- β -driven fibrotic pathway. Restoration of **** functions as a key negative regulator of the TGF- β pathway. Molecular intervention using **** mRNA is expected to normalize the pro-fibrotic microenvironment, attenuate fibroblast activation, and limit the pathological extracellular matrix deposition.
Competitiveness	Current approved treatments of IPF are oral TGF- β modulators. Unfortunately, they have limited therapeutic effectiveness due to side effects. By leveraging our proprietary pulmonary selective delivery platforms, improved therapeutic outcomes are anticipated through lower systemic exposure and enhanced local drug availability. By capitalizing on the favorable pharmacokinetic profile of mRNA therapeutics, reduced dosing frequency relative to the current twice a daily oral regimen is expected to improve patient safety, enhanced efficacy and quality of life.
Development Stage	Candidate
Route of Administration	Intravenous injection or inhalation

Any unauthorized distribution or reproduction of this material is strictly prohibited.